Published in Medical Letter on the CDC and FDA, February 29th, 2004
If the U.S. Food and Drug Administration accepts the application, Provectus hopes to begin enrolling patients by mid-2004.
Provectus has successfully completed a full range of preclinical studies in laboratory models. Additionally, Provecta has been used to treat a number of spontaneous tumors in veterinary subjects.
"We are extremely pleased to begin moving this drug through the regulatory process in a manner which we hope will result in Fast Track consideration by the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA